SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-033118
Filing Date
2022-11-21
Accepted
2022-11-21 16:31:35
Documents
56
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1226013
2 ex31-1.htm EX-31.1 17413
3 ex32-1.htm EX-32.1 7517
  Complete submission text file 0001493152-22-033118.txt   5176713

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE endv-20220930.xsd EX-101.SCH 45037
5 XBRL CALCULATION FILE endv-20220930_cal.xml EX-101.CAL 44019
6 XBRL DEFINITION FILE endv-20220930_def.xml EX-101.DEF 207889
7 XBRL LABEL FILE endv-20220930_lab.xml EX-101.LAB 375668
8 XBRL PRESENTATION FILE endv-20220930_pre.xml EX-101.PRE 277078
50 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 697997
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 221406182
SIC: 2834 Pharmaceutical Preparations